Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Malaria vaccine live unattenuated plus chloroquine - Sanaria

Drug Profile

Malaria vaccine live unattenuated plus chloroquine - Sanaria

Alternative Names: PfSPZ Challenge plus chloroquine; PfSPZ CVac; PfSPZ malaria vaccine live unattenuated plus chloroquine - Sanaria; Plasmodium falciparum sporozoite vaccine live unattenuated plus chloroquine - Sanaria

Latest Information Update: 09 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanaria
  • Developer National Institute of Allergy and Infectious Diseases; Sanaria; University of Tubingen
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Falciparum malaria

Most Recent Events

  • 01 Jul 2022 University Hospital Tuebingen in collaboration with Sanaria plans a phase I/II trial in Malaria (IV, Injection) in October 2022 (NCT05441410)
  • 30 May 2022 Phase-II clinical trials in Falciparum malaria (In adults, Prevention) in Indonesia (IV) (NCT03503058)
  • 27 Feb 2020 University of Oxford in collaboration with Sanaria plans a phase I/II trial for Malaria (In volunteers) in Kenya (NCT04280692)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top